Catalyst Pharmaceuticals, Inc. $CPRX Position Boosted by Profund Advisors LLC

Profund Advisors LLC lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 61,076 shares of the biopharmaceutical company’s stock after acquiring an additional 23,304 shares during the quarter. Profund Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,426,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in CPRX. Federated Hermes Inc. grew its position in Catalyst Pharmaceuticals by 52.8% in the third quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company’s stock worth $7,669,000 after buying an additional 134,509 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of Catalyst Pharmaceuticals by 1,216.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company’s stock valued at $3,260,000 after acquiring an additional 152,925 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Catalyst Pharmaceuticals by 10.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company’s stock worth $10,180,000 after acquiring an additional 50,343 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after acquiring an additional 770,198 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 64.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock worth $3,094,000 after acquiring an additional 61,328 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent analyst reports. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday. Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Finally, Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Stock Up 0.1%

CPRX opened at $31.25 on Thursday. The firm has a market capitalization of $3.82 billion, a P/E ratio of 17.96, a PEG ratio of 0.91 and a beta of 0.72. The stock has a fifty day moving average of $26.55 and a 200-day moving average of $24.57. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).